Comparative Pharmacology
Head-to-head clinical analysis: AMPICILLIN SODIUM versus KLEBCIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMPICILLIN SODIUM versus KLEBCIL.
AMPICILLIN SODIUM vs KLEBCIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ampicillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
Klebcillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.
1-2 g IV/IM every 4-6 hours for serious infections; maximum 12 g/day.
KLEBCIL (ceftazidime-avibactam) 2.5 g (ceftazidime 2 g + avibactam 0.5 g) IV every 8 hours infused over 2 hours.
None Documented
None Documented
Terminal elimination half-life ~1 hour in healthy adults; prolonged to 2–5 hours in renal impairment (CrCl <10 mL/min) and up to 7–20 hours in anuria; neonatal half-life 2–4 hours.
2-3 hours (prolonged to 30-60 hours in severe renal impairment; adjust dosing)
Approximately 90% renal excretion via tubular secretion and glomerular filtration; small biliary excretion (<10%); fecal elimination negligible.
Primarily renal (70-80% unchanged); minor biliary/fecal (15-20%)
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic